Expert consensus on the detection and clinical application of tumor mutational burden
Zhenying Guo, Chunqiang Xu, Shirong Zhang, Yue Hao et autres
As an emerging biomarker, tumor mutational burden (TMB) has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy. Currently, TMB is detected primarily by whole-exome sequencing or targeted panel sequencing on high-throughput sequencing platforms. However, the lack of uniformity …
cn, Éthiopie, hk (code pays fourni par la source)
0 citations
Cancer Biology and Medicine